by B2i | Jul 19, 2024 | Press Releases
GAITHERSBURG, Md., July 19, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
by B2i | Jun 18, 2024 | Press Releases
Current CFO, Michael Vander Hoek, transitions to full-time Vice President, RegulatoryGAITHERSBURG, Md., June 18, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty...
by B2i | May 22, 2024 | Press Releases
GAITHERSBURG, Md., May 22, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...
by B2i | May 14, 2024 | Press Releases
GAITHERSBURG, Md., May 14, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
by B2i | Apr 23, 2024 | Press Releases
GAITHERSBURG, Md., April 23, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”),...
by B2i | Apr 3, 2024 | Press Releases
Webcasted presentation to take place at 3:10pm ETGAITHERSBURG, Md., April 03, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients...